DANIEL HOLLANDER, M.D.; ROBERT T. MANNING, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Wegener's granulomatosis, a rare disease of unknown etiology, was first described by Klinger (1) in 1931. Wegener (2), in 1936, reported three additional patients, recognizing the syndrome as a distinct clinicopathological entity. He believed it to be related to periarteritis nodosa.
Clinically, Wegener's granulomatosis is characterized by necrotizing granulomatous lesions of the upper or lower respiratory tract, generalized necrotizing angiitis involving both arteries and veins, and focal necrotizing glomerulonephritis (3).
Antibiotics (4), adrenocorticosteroids (5), and radiotherapy (4, 6) have been used in the management of this disorder. The average survival time of patients is 5 months, the most common causes
HOLLANDER D, MANNING RT. The Use of Alkylating Agents in the Treatment of Wegener's Granulomatosis. Ann Intern Med. ;67:393–398. doi: 10.7326/0003-4819-67-2-393
Download citation file:
Published: Ann Intern Med. 1967;67(2):393-398.
Autoimmune Kidney Disease, Interstitial Lung Disease, Nephrology, Pulmonary/Critical Care, Rheumatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use